Begin main content

Pembrolizumab (Keytruda) for Renal Cell Carcinoma — Details

Project Number pCODR 10185
Brand Name Keytruda
Generic Name Pembrolizumab
Tumour Type Genitourinary
Indication Renal Cell Carcinoma
Funding Request For the treatment of patients with advanced renal cell carcinoma (RCC) in combination with axinitib, as first-line treatment.
Review Status Under Review
Pre Noc Submission Yes
NOC Date
Manufacturer Merck Canada
Sponsor Merck Canada
Submission Date August 2, 2019
Submission Deemed Complete August 19, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ August 19, 2019
Check-point meeting October 30, 2019
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.